Sonia Raffe

Naidoo et al. Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial. Lancet HIV. 2026 Jan; 13(1): e9-e20. doi: 10.1016/S2352-3018(25)00200-0.

Ring K, Elias A, Devonald M, et al. Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV. HIV Med. June 13, 2025.

Advanced HIV disease (AHD)—defined by a CD4 count 3—is associated with poor health outcomes. This study used household surveys from 13 countries in Sub-Saharan Africa to estimate the proportion of all people with AHD in the region. Among 28 040 surveyed people with HIV (65% female, median age 38, 53% resident in rural areas), AHD was found in nearly 10% (n=2261). AHD was associated with male sex and older age but not with rural versus urban location or economic status. Based on HIV prevalence data, nearly 2 million people were estimated to have AHD in Sub-Saharan Africa. The findings highlight the continued need for comprehensive HIV care alongside antiretroviral therapy provision in the region.

Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2024 Nov 27. doi: 10.1056/NEJMoa2411858. Epub ahead of print. PMID: 39602624

Farahani M, Killian R., Reid GA, et al. Prevalence of syphilis among adults and adolescents in five sub-Saharan African countries: findings from Population-based HIV Impact Assessment surveys. Lancet Glob Health. 2024;12:e1413–23.

Zhang Y, Li J, Xie Y, et al. Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial. Nat Med. 2023;29:2241–2247.

Ando N, Mizushima D, Takano M, et al. Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study. Journal of Antimicrobial Chemotherapy, 788, pp.2070–2079.

Hofmann E, Surial B, Boillat-Blanco N, et al. Swiss HIV Cohort Study. Hepatitis B virus (HBV) replication during tenofovir therapy is frequent in HIV/HBV coinfection. Clin Infect Dis 2023;76:730–3.